Management of PSVT in Patients with Reduced LVEF

Initial Management Approach

The European Society of Cardiology recommends electrical cardioversion as the treatment of choice for hemodynamically unstable patients with PSVT 1
For hemodynamically stable PSVT with reduced ejection fraction, the initial management approach should be vagal maneuvers followed by adenosine, as per standard PSVT management 1
If pharmacological cardioversion is required and the patient has structural heart disease or reduced LVEF, amiodarone is the recommended antiarrhythmic agent, according to the European Heart Journal 1

The European Heart Journal recommends intravenous amiodarone for cardioversion of atrial fibrillation in patients with heart failure with reduced ejection fraction (HFrEF) 1
Flecainide and propafenone are contraindicated in patients with HFrEF, severe left ventricular hypertrophy, or coronary artery disease, as stated by the European Heart Journal 1
Vernakalant is contraindicated in patients with recent ACS, HFrEF, or severe aortic stenosis, according to the European Heart Journal 1
Beta-blockers can worsen hypotension in hemodynamically compromised patients, as noted by the European Heart Journal and Praxis Medical Insights 1, 2

For a patient with LVEF 40% and PSVT, the optimal management strategy includes attempting vagal maneuvers first, followed by adenosine administration, and considering electrical cardioversion rather than pharmacological options if adenosine fails 1, 2
If pharmacological therapy is necessary, amiodarone is the safest antiarrhythmic choice given the reduced LVEF, as recommended by the European Heart Journal and Praxis Medical Insights 1, 2
Optimal heart failure medical therapy with beta-blockers, ACE inhibitors/ARBs, and mineralocorticoid receptor antagonists is also essential, as stated by the European Heart Journal 3, 4

For acute PSVT termination, an initial loading dose of 150 mg IV amiodarone over 10 minutes may be repeated in 10-30 minutes if necessary, as recommended by Praxis Medical Insights 2

Amiodarone should not be used in patients with pre-excitation syndromes (Wolff-Parkinson-White), as it may increase ventricular response and potentially cause ventricular fibrillation, according to Praxis Medical Insights 2
Pharmacological cardioversion is not recommended for patients with sinus node dysfunction, atrioventricular conduction disturbances, or prolonged QTc (>500 ms), as stated by the European Heart Journal 1